Cargando…

SREBP1 siRNA enhance the docetaxel effect based on a bone-cancer dual-targeting biomimetic nanosystem against bone metastatic castration-resistant prostate cancer

Until recently, there have been limited options for patients with bone metastatic castration-resistant prostate cancer (BmCRPC) following the failure of or development of resistance to docetaxel (DTX), which is one of the frontline treatments. Sterol regulatory element-binding protein 1 (SREBP1) is...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Jiyuan, Wu, Zhenjie, Ding, Weihong, Xiao, Chengwu, Zhang, Yu, Gao, Shen, Gao, Yuan, Cai, Weimin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6993241/ https://www.ncbi.nlm.nih.gov/pubmed/32042326 http://dx.doi.org/10.7150/thno.40489

Ejemplares similares

Development and Evaluation of a PSMA-Targeted Nanosystem Co-Packaging Docetaxel and Androgen Receptor siRNA for Castration-Resistant Prostate Cancer Treatment
por: Zhang, Yingying, et al.
Publicado: (2022)

Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Multifunctional nanosystems: growing sanguinity in siRNA therapy
por: Badrealam, Khan Farheen, et al.
Publicado: (2014)

Biopolymer-Based Nanosystems for siRNA Drug Delivery to Solid Tumors including Breast Cancer
por: Subhan, Md Abdus, et al.
Publicado: (2023)

CRPC Membrane-Camouflaged, Biomimetic Nanosystem for Overcoming Castration-Resistant Prostate Cancer by Cellular Vehicle-Aided Tumor Targeting
por: Lu, Kai, et al.
Publicado: (2022)

Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer
por: Zhang, Xiangyu, et al.
Publicado: (2019)

Bone site-specific delivery of siRNA
por: Liu, Xinli
Publicado: (2016)

siRNA goes after diseases of the bone
por: Coles, Andrew H.
Publicado: (2023)

Synergistic treatment of osteosarcoma with biomimetic nanoparticles transporting doxorubicin and siRNA
por: Zhao, Jingtong, et al.
Publicado: (2023)

Mechanisms of PDGF siRNA-mediated inhibition of bone cancer pain in the spinal cord
por: Xu, Yang, et al.
Publicado: (2016)

Activatable “Matryoshka” nanosystem delivery NgBR siRNA and control drug release for stepwise therapy and evaluate drug resistance cancer
por: Xu, Xinzhi, et al.
Publicado: (2022)

GE11 peptide-conjugated nanoliposomes to enhance the combinational therapeutic efficacy of docetaxel and siRNA in laryngeal cancers
por: Xu, Wei-Wei, et al.
Publicado: (2017)

A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis
por: Cui, Yongzhi, et al.
Publicado: (2021)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
por: Francini, Filippo, et al.
Publicado: (2011)

Neuronal mitochondria-targeted therapy for Alzheimer’s disease by systemic delivery of resveratrol using dual-modified novel biomimetic nanosystems
por: Han, Yang, et al.
Publicado: (2020)

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer
por: Mahon, K L, et al.
Publicado: (2015)

Clinical activity of abiraterone plus prednisone in docetaxel-naïve and docetaxel-resistant Chinese patients with metastatic castration-resistant prostate cancer
por: Lin, Guo-Wen, et al.
Publicado: (2019)

Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations
por: Li, Xiangyan, et al.
Publicado: (2015)

Targeted Co-Delivery of Docetaxel and cMET siRNA for Treatment of Mucin1 Overexpressing Breast Cancer Cells
por: Majidi Zolbanin, Naime, et al.
Publicado: (2018)

Polymer-based nanosystems and their applications in bone anticancer therapy
por: Nafo, Wanis
Publicado: (2023)

Bone scaffolds loaded with siRNA-Semaphorin4d for the treatment of osteoporosis related bone defects
por: Zhang, Yufeng, et al.
Publicado: (2016)

Microfluidic-Based Cationic Cholesterol Lipid siRNA Delivery Nanosystem: Highly Efficient In Vitro Gene Silencing and the Intracellular Behavior
por: Zhu, Zhaoyuan, et al.
Publicado: (2022)

Loading of ”cocktail siRNAs” into extracellular vesicles via TAT-DRBD peptide for the treatment of castration-resistant prostate cancer
por: Diao, Yanjun, et al.
Publicado: (2022)

siRNA-Mediated Silencing of CIP2A Enhances Docetaxel Activity Against PC-3 Prostate Cancer Cells
por: Razi Soofiyani, Saiedeh, et al.
Publicado: (2017)

Cooperative Treatment of Gastric Cancer Using B7-H7 siRNA and Docetaxel; How Could They Modify Their Effectiveness?
por: Bolandi, Nadia, et al.
Publicado: (2023)

Biomimetism, biomimetic matrices and the induction of bone formation
por: Ripamonti, Ugo
Publicado: (2009)

Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer
por: Wilson, C, et al.
Publicado: (2008)

Docetaxel in very elderly men with metastatic castration-resistant prostate cancer
por: Wong, Hui-Li, et al.
Publicado: (2015)

Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
por: Conteduca, Vincenza, et al.
Publicado: (2019)

γ-Klotho is correlated with resistance to docetaxel in castration-resistant prostate cancer
por: Onishi, Kenta, et al.
Publicado: (2020)

Cabazitaxel versus docetaxel for treatment of metastatic castrate refractory prostate cancer
por: James, Nicholas D., et al.
Publicado: (2022)

Biomimetic doxorubicin/ginsenoside co-loading nanosystem for chemoimmunotherapy of acute myeloid leukemia
por: Chen, Mo, et al.
Publicado: (2022)

Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles
por: Ballarín-González, Borja, et al.
Publicado: (2013)

Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer
por: Uemura, Koichi, et al.
Publicado: (2016)

Lipoprotein-biomimetic nanostructure enables efficient targeting delivery of siRNA to Ras-activated glioblastoma cells via macropinocytosis
por: Huang, Jia-Lin, et al.
Publicado: (2017)

Potent antitumour of the mTORC1/2 dual inhibitor AZD2014 in docetaxel‐sensitive and docetaxel‐resistant castration‐resistant prostate cancer cells
por: Li, Senmao, et al.
Publicado: (2021)

Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study
por: Petrioli, R, et al.
Publicado: (2011)

Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
por: Ku, ShengYu, et al.
Publicado: (2014)

The Influence of Prednisone on the Efficacy of Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer
por: Teply, Benjamin A., et al.
Publicado: (2015)

Inhibiting autophagy overcomes docetaxel resistance in castration-resistant prostate cancer cells
por: Wang, Quan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_44a3akh55alf4k5p5o91sj1oms